Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.56 |
| ▸ | JAK3 | P52333 | 5/20 | 0.56 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423683 | 0.92 | JAK2 (0.54) | JAK2JAK3AKT3ABL1PDGFRB | |
| SCHEMBL13154242 | 0.92 | JAK2 (0.46) | JAK2JAK3AKT3CAMK2DMCHR1 | |
| SCHEMBL13154245 | 0.91 | JAK2 (0.53) | JAK2JAK3AKT3CAMK2DABL1 | |
| SCHEMBL12423747 | 0.90 | JAK2 (0.46) | JAK2JAK3AKT3CAMK2DABL1 | |
| SCHEMBL13154243 | 0.87 | JAK2 (0.57) | JAK2JAK3AKT3ABL1PDGFRB | |
| SCHEMBL12423670 | 0.84 | JAK2 (0.46) | JAK2JAK3AKT3ABL1PDGFRB | |
| SCHEMBL12423669 | 0.84 | JAK2 (0.53) | JAK2JAK3AKT3ABL1PDGFRB | |
| SCHEMBL12423677 | 0.83 | JAK2 (0.45) | JAK2JAK3AKT3ABL1PDGFRB | |
| SCHEMBL13154252 | 0.82 | JAK2 (0.55) | JAK2JAK3AKT3ABL1PDGFRB | |
| SCHEMBL12423671 | 0.81 | JAK2 (0.45) | JAK2JAK3AKT3ABL1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | MAP3K20, MAP3K6, MAP4K2 | JAK2 217/4885JAK3 108/4885AKT3 340/4885 |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | MAP3K20, MAP3K6, MAP4K2 | JAK2 217/4885JAK3 108/4885AKT3 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.